Pomalidomide
- Generic Name
- Pomalidomide
- Brand Names
- Imnovid, Pomalyst, Imnovid (previously Pomalidomide Celgene), Pomalidomide Viatris, Pomalidomide Zentiva, Pomalidomide Krka, Pomalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C13H11N3O4
- CAS Number
- 19171-19-8
- Unique Ingredient Identifier
- D2UX06XLB5
- Background
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
- Indication
Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and have demonstrated disease progression on or within 60 days of completion of the last therapy. It is also indicated for the treatment of Kaposi's sarcoma (KS) in AIDS patients who have failed highly active antiretroviral thera...
- Associated Conditions
- Kaposi's Sarcoma, Multiple Myeloma (MM)
- Associated Therapies
- -
CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas
- First Posted Date
- 2007-10-08
- Last Posted Date
- 2013-03-13
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 23
- Registration Number
- NCT00540579
- Locations
- 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸Tennessee Oncology, PLLC, Nashville, Tennessee, United States
A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide
- Conditions
- Interventions
- First Posted Date
- 2007-10-01
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Celgene
- Target Recruit Count
- 22
- Registration Number
- NCT00537511
- Locations
- 🇺🇸
Pennsylvania State University, Hershey, Pennsylvania, United States
🇺🇸Ireland Cancer Center, Case Western Reserve University, Division of Hematology/Oncology, Cleveland, Ohio, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia
- First Posted Date
- 2007-04-20
- Last Posted Date
- 2019-11-20
- Lead Sponsor
- Celgene
- Target Recruit Count
- 88
- Registration Number
- NCT00463385
- Locations
- 🇦🇹
Medical University of Vienna, Department of Internal Medicine, Hematology, Vienna, Austria
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸New York Presbyterian HospitalWeill Medical College of Cornell University, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.